PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 138 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,483,775 | +435.3% | 1,108,140 | +250.1% | 0.05% | +350.0% |
| Q4 2022 | $3,453,015 | -83.9% | 316,500 | -87.5% | 0.01% | -85.9% |
| Q3 2022 | $21,395,000 | -35.5% | 2,537,993 | -39.4% | 0.08% | -39.3% |
| Q2 2022 | $33,153,000 | -52.0% | 4,191,200 | +43.8% | 0.14% | -48.9% |
| Q1 2022 | $69,030,000 | -16.6% | 2,915,100 | +20.5% | 0.27% | -17.0% |
| Q4 2021 | $82,756,000 | +6.4% | 2,419,763 | -44.8% | 0.33% | -3.2% |
| Q3 2021 | $77,743,000 | +50.0% | 4,387,300 | +279.8% | 0.34% | +46.4% |
| Q2 2021 | $51,845,000 | +112.4% | 1,155,200 | +22.6% | 0.23% | +104.4% |
| Q1 2021 | $24,406,000 | +120.1% | 942,300 | +71.3% | 0.11% | +111.1% |
| Q4 2020 | $11,088,000 | +468.0% | 550,000 | +238.5% | 0.05% | +350.0% |
| Q3 2019 | $1,952,000 | -21.8% | 162,500 | +35.4% | 0.01% | +9.1% |
| Q4 2017 | $2,496,000 | – | 120,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $43,400,000 | 3.81% |
| BVF INC/IL | 3,901,759 | $69,139,000 | 2.70% |
| COMMODORE CAPITAL LP | 498,079 | $8,826,000 | 2.33% |
| Altium Capital Management LP | 346,000 | $6,131,000 | 1.61% |
| Twin Lakes Capital Management, LLC | 139,287 | $2,468,000 | 1.45% |
| Opaleye Management Inc. | 330,222 | $5,852,000 | 1.09% |
| EcoR1 Capital, LLC | 1,443,800 | $25,584,000 | 0.89% |
| OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | 776,689 | $13,763,000 | 0.76% |
| JABODON PT CO | 90,656 | $1,606,000 | 0.66% |
| Artal Group S.A. | 1,500,000 | $26,580,000 | 0.60% |